$VIVS earnings report

VivoSim Labs reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, confirmed compliance with Nasdaq Listing Rule 5550(b)(1), and anticipates 500%+ revenue growth in fiscal year 2027. AlphaAI read VivoSim Labs's Not disclosed filing as mixed.

Not disclosed

alphai · Earnings readVIVS · Not disclosed

VivoSim Labs reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, confirmed compliance with Nasdaq Listing Rule 5550(b)(1), and anticipates 500%+ revenue growth in fiscal year 2027.

Mixed quarter

The filing provides a favorable fiscal year 2027 revenue-growth outlook and confirms Nasdaq minimum-stockholders'-equity compliance, but it does not disclose reported-period revenue, profitability, margins, cash flow, or operating metrics. The cash figure is preliminary and subject to financial closing procedures and final adjustments.

fiscal year 2027 outlook
500%+ revenue growth

Key metrics

as reported
MetricValueq/qy/y
Preliminary cash on handotherapproximately $10.1 million

fiscal year 2027 outlook

  • Revenue500%+ revenue growth

What drove it

  • The Company anticipates 500%+ revenue growth in its fiscal year 2027.
  • The Nasdaq Listing Qualifications Staff determined that the Company currently complies with Nasdaq Listing Rule 5550(b)(1), which requires registrants to maintain a minimum stockholders’ equity balance of $2.5 million.

Concerns

  • The preliminary financial information reflects management’s current estimates and could be impacted by financial closing procedures, final adjustments, and other developments.
  • The filing does not provide an actual revenue figure, profitability measures, margins, operating cash flow, free cash flow, or debt.
  • The fiscal year 2027 revenue outlook is expressed only as 500%+ revenue growth, without a revenue base, revenue range, or other financial guidance.

What to watch

  • Finalization of the preliminary cash-on-hand figure following financial closing procedures and final adjustments.
  • Reported fiscal year 2027 revenue and the base against which the anticipated 500%+ revenue growth will be measured.
  • Continued compliance with Nasdaq Listing Rule 5550(b)(1).

Balance sheet and cash flow

  • Preliminary cash on hand as of August 3, 2026 was approximately $10.1 million.

Analysis

This Item 2.02 filing is a preliminary financial and corporate-status update rather than a complete earnings release. VivoSim Labs disclosed preliminary cash on hand of approximately $10.1 million as of August 3, 2026, but did not provide a fiscal reporting period, income statement, balance sheet, or cash flow statement.

The principal forward-looking disclosure is that the Company anticipates 500%+ revenue growth in its fiscal year 2027. The filing does not state the revenue amount from which this growth will be measured, nor does it provide revenue guidance in dollars, segment detail, gross-margin guidance, operating-expense guidance, tax-rate guidance, or profitability targets.

The company also disclosed that Nasdaq Listing Qualifications Staff determined that it currently complies with Nasdaq Listing Rule 5550(b)(1). The filing describes that rule as requiring registrants to maintain a minimum stockholders’ equity balance of $2.5 million. This is a listing-compliance determination, not a reported stockholders’ equity balance for VivoSim Labs.

The preliminary nature of the cash disclosure is important. Management stated that the information is based on currently available information and could be affected by financial closing procedures, final adjustments, and other developments. Investors will need the underlying periodic financial statements to assess revenue conversion, operating losses or income, cash burn, debt, and the durability of the fiscal year 2027 growth outlook.

No capital-return activity, debt balance, operating cash flow, free cash flow, segment performance, GAAP results, non-GAAP results, or executive commentary was included in the provided filing text. Accordingly, the disclosed outlook and preliminary liquidity figure are the only financial datapoints available for this read.

Not in the filing

stated, not guessed
  • Fiscal reporting period and period-end date.
  • Actual total revenue and prior-year and prior-quarter revenue comparisons.
  • Revenue growth for any reported period.
  • Segment revenue, segment growth rates, and segment drivers.
  • GAAP gross profit, gross margin, operating expenses, operating income or loss, net income or loss, and earnings per share.
  • Non-GAAP gross margin, operating income or loss, net income or loss, and earnings per share.
  • Operating cash flow and free cash flow.
  • Cash-flow comparisons to prior periods.
  • Debt, reported stockholders’ equity, and other balance-sheet balances.
  • Share repurchases, dividends, and other capital-return activity.
  • Fiscal year 2027 revenue amount or range, revenue comparison base, gross-margin guidance, operating-expense guidance, tax-rate guidance, and other financial guidance.
  • Prior-period guidance for comparison.
  • Named executive quotes or CFO commentary.

AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about VIVS earnings dates

When is VivoSim Labs's next earnings date?
AlphaAI has no confirmed date for VIVS yet. We publish an earnings date only once the company has set it, so this page shows one the day that happens.
Where does the date come from, and why is there no estimate?
A confirmed date comes from the company's own announcement. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so AlphaAI shows nothing until the company confirms. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.
VIVS Earnings Date & Report — VivoSim Labs Results | alphai